These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 8277068

  • 1. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1.
    O'Connor CM, Meese R, Carney R, Smith J, Conn E, Burks J, Hartman C, Roark S, Shadoff N, Heard M.
    J Am Coll Cardiol; 1994 Jan; 23(1):11-8. PubMed ID: 8277068
    [Abstract] [Full Text] [Related]

  • 2. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial.
    Cannon CP, McCabe CH, Diver DJ, Herson S, Greene RM, Shah PK, Sequeira RF, Leya F, Kirshenbaum JM, Magorien RD.
    J Am Coll Cardiol; 1994 Dec; 24(7):1602-10. PubMed ID: 7963104
    [Abstract] [Full Text] [Related]

  • 3. Anistreplase versus alteplase in acute myocardial infarction: comparative effects on left ventricular function, morbidity and 1-day coronary artery patency. The TEAM-3 Investigators.
    Anderson JL, Becker LC, Sorensen SG, Karagounis LA, Browne KF, Shah PK, Morris DC, Fintel DJ, Mueller HS, Ross AM.
    J Am Coll Cardiol; 1992 Oct; 20(4):753-66. PubMed ID: 1527286
    [Abstract] [Full Text] [Related]

  • 4. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.
    Lancet; 1992 Mar 28; 339(8796):753-70. PubMed ID: 1347801
    [Abstract] [Full Text] [Related]

  • 5. Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function.
    Bassand JP, Machecourt J, Cassagnes J, Anguenot T, Lusson R, Borel E, Peycelon P, Wolf E, Ducellier D.
    J Am Coll Cardiol; 1989 Apr 28; 13(5):988-97. PubMed ID: 2647817
    [Abstract] [Full Text] [Related]

  • 6. Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS).
    Neuhaus KL, von Essen R, Tebbe U, Vogt A, Roth M, Riess M, Niederer W, Forycki F, Wirtzfeld A, Maeurer W.
    J Am Coll Cardiol; 1992 Apr 28; 19(5):885-91. PubMed ID: 1552106
    [Abstract] [Full Text] [Related]

  • 7. Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study.
    Bassand JP, Cassagnes J, Machecourt J, Lusson JR, Anguenot T, Wolf JE, Maublant J, Bertrand B, Schiele F.
    Circulation; 1991 Sep 28; 84(3):1107-17. PubMed ID: 1909218
    [Abstract] [Full Text] [Related]

  • 8. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.
    Anderson JL, Rothbard RL, Hackworthy RA, Sorensen SG, Fitzpatrick PG, Dahl CF, Hagan AD, Browne KF, Symkoviak GP, Menlove RL.
    J Am Coll Cardiol; 1988 Jun 28; 11(6):1153-63. PubMed ID: 3284943
    [Abstract] [Full Text] [Related]

  • 9. A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction. The DUCCS-II Investigators.
    O'Connor CM, Meese RB, McNulty S, Lucas KD, Carney RJ, LeBoeuf RM, Maddox W, Bethea CF, Shadoff N, Trahey TF, Heinsimer JA, Burks JM, O'Donnell G, Krucoff MW, Califf RM.
    Am J Cardiol; 1996 Apr 15; 77(10):791-7. PubMed ID: 8623729
    [Abstract] [Full Text] [Related]

  • 10. The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction.
    Meinertz T, Kasper W, Schumacher M, Just H.
    Am J Cardiol; 1988 Sep 01; 62(7):347-51. PubMed ID: 3046283
    [Abstract] [Full Text] [Related]

  • 11. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
    Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS, Becker RC, Kleiman NS, Haugland JM, Anderson JL.
    J Am Coll Cardiol; 1994 Apr 01; 23(5):993-1003. PubMed ID: 8144799
    [Abstract] [Full Text] [Related]

  • 12. Comparison in acute myocardial infarction of anisoylated plasminogen streptokinase activator complex versus heparin evaluated by simultaneous thallium-201/technetium-99m pyrophosphate tomography.
    Krause T, Kasper W, Meinertz T, Schnitzler M, Just H, Schümichen C, Moser E.
    Am J Cardiol; 1993 Jan 01; 71(1):8-13. PubMed ID: 8420241
    [Abstract] [Full Text] [Related]

  • 13. [Anisoylated plasminogen streptokinase complex during the acute phase of myocardial infarction. Results of a multicenter double-blind study versus heparin].
    Cassagnes J, Bassand JP, Machecourt J, Lusson JR, Anguenot T, Borel E, Vacher D, Denis B, Maurat JP, Jallut H.
    Arch Mal Coeur Vaiss; 1990 Apr 01; 83(4):453-60. PubMed ID: 2111665
    [Abstract] [Full Text] [Related]

  • 14. Effects on infarct size and left ventricular function of early intravenous injection of anistreplase in acute myocardial infarction. The APSIM Study Investigators.
    Bassand JP, Bernard Y, Lusson JR, Machecourt J, Cassagnes J, Borel E.
    Clin Cardiol; 1990 Mar 01; Suppl 5():V39-44; discussion V67-72. PubMed ID: 2182240
    [Abstract] [Full Text] [Related]

  • 15. Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction. Preliminary data from a randomised multicentre study.
    Brochier ML, Quilliet L, Kulbertus H, Materne P, Letac B, Cribier A, Monassier JP, Sacrez A, Favier JP.
    Drugs; 1987 Mar 01; 33 Suppl 3():140-5. PubMed ID: 3315581
    [Abstract] [Full Text] [Related]

  • 16. Limitation of myocardial infarct size and preservation of left ventricular function by early administration of APSAC in myocardial infarction.
    Bassand JP, Machecourt J, Cassagnes J, Lusson JR, Borel E, Schiele F.
    Am J Cardiol; 1989 Jul 05; 64(2):18A-23A; discussion 24A-26A. PubMed ID: 2662738
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of 2 intravenous thrombolytic agents (anisoylated plasminogen streptokinase activator complex versus streptokinase) in patients with acute myocardial infarction.
    Seabra-Gomes R, Aniceto Silva J, Aleixo A, Real T, Freire I, Torres I, Freitas R, Crespo F.
    Drugs; 1987 Jul 05; 33 Suppl 3():169-74. PubMed ID: 3315586
    [Abstract] [Full Text] [Related]

  • 18. Anisoylated plasminogen streptokinase activator complex in acute myocardial infarction: a placebo-controlled arteriographic coronary recanalization study.
    Timmis AD, Griffin B, Crick JC, Sowton E.
    J Am Coll Cardiol; 1987 Jul 05; 10(1):205-10. PubMed ID: 3298360
    [Abstract] [Full Text] [Related]

  • 19. Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO.
    Bates ER.
    Chest; 1992 Apr 05; 101(4 Suppl):140S-150S. PubMed ID: 1555479
    [Abstract] [Full Text] [Related]

  • 20. Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction.
    Bossaert LL.
    Drugs; 1987 Apr 05; 33 Suppl 3():287-92. PubMed ID: 3315610
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.